Could a common diabetes drug stop diabetes after kidney transplant?
NCT ID NCT07682350
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial tests whether taking dapagliflozin (Forxiga) for 12 months can prevent post-transplant diabetes in kidney transplant recipients who do not have diabetes. The study includes 184 adults who recently received a kidney transplant and are on standard immunosuppressive therapy. Participants are randomly assigned to receive either dapagliflozin or a placebo, and researchers monitor diabetes development, kidney function, and safety over a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (Forxiga)
What this could lead to
If it works, this could offer a way to prevent diabetes after kidney transplant, helping patients avoid a lifelong condition and protecting their new kidney.
What could go wrong
This is a Phase 2 trial with 184 participants, so results are preliminary. The drug may not reduce diabetes risk or could cause side effects like urinary infections or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mindfulness Therapy for Early Psychosis (NCT07645443)
- SGLT2 Inhibitors in Kidney Transplant: INFINITI NCT04965935
- CMV Immune Response in Kidney Transplants – NCT07621835
- Shock Wave Therapy for Leg Swelling Trial NCT07626645
- COPE Program for Breast Cancer Patients (NCT07610499)
- Thyroid & Liver Disease Study | NCT07603817
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nephrology and Endocrinology.
Copenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Nephrology, Odense University Hospital
Odense, 5000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Renal Medicine
Aarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••